We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
2051
DELISTED
Immunogen Inc
IMGN
| $137K | ﹤0.01% |
30,392
-209,929
| -87% | -$912K |
|
|
VMEO
2052
DELISTED
Vimeo
VMEO
| $135K | ﹤0.01% |
22,587
-74,414
| -77% | -$675K |
|
2053
Alphatec Holdings
ATEC
$1.47B
| $132K | ﹤0.01% |
20,250
-168
| -0.8% | -$1.55K |
|
2054
Solid Biosciences
SLDB
$918M
| $129K | ﹤0.01% |
13,988
-10,541
| -43% | -$110K |
|
|
USX
2055
DELISTED
U.S. Xpress Enterprises, Inc. Class A Common Stock
USX
| $129K | ﹤0.01% |
48,319
-60,157
| -55% | -$187K |
|
|
MNTV
2056
DELISTED
Momentive Global Inc. Common Stock
MNTV
| $128K | ﹤0.01% |
14,559
-50,544
| -78% | -$677K |
|
|
EPZM
2057
DELISTED
Epizyme, Inc
EPZM
| $127K | ﹤0.01% |
86,478
-371,192
| -81% | -$273K |
|
|
CONN
2058
DELISTED
Conn's Inc.
CONN
| $126K | ﹤0.01% |
15,745
+5,255
| +50% | +$69K |
|
|
SPPI
2059
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $126K | ﹤0.01% |
161,832
+127,252
| +368% | +$112K |
|
2060
Acacia Research
ACTG
$465M
| $125K | ﹤0.01% |
+24,773
| New | +$114K |
|
2061
FIGS
FIGS
$2.39B
| $125K | ﹤0.01% |
+13,674
| New | +$174K |
|
2062
Harvard Bioscience
HBIO
$28.8M
| $124K | ﹤0.01% |
3,436
-19,025
| -85% | -$859K |
|
|
TWO
2063
Two Harbors Investment
TWO
$1.26B
| $124K | ﹤0.01% |
6,219
-6,019
| -49% | -$122K |
|
2064
Annexon
ANNX
$883M
| $121K | ﹤0.01% |
32,021
-26,860
| -46% | -$82.1K |
|
|
OSG
2065
Octave Specialty Group
OSG
$210M
| $120K | ﹤0.01% |
10,611
-14,414
| -58% | -$137K |
|
2066
Cardiff Oncology
CRDF
$80.1M
| $120K | ﹤0.01% |
54,580
-308,703
| -85% | -$517K |
|
2067
Frontline
FRO
$8.56B
| $120K | ﹤0.01% |
+13,517
| New | +$122K |
|
|
TECX
2068
Tectonic Therapeutic
TECX
$639M
| $120K | ﹤0.01% |
10,900
-30,598
| -74% | -$361K |
|
|
GHL
2069
DELISTED
Greenhill & Co., Inc.
GHL
| $120K | ﹤0.01% |
+13,001
| New | +$160K |
|
|
LUNA
2070
DELISTED
Luna Innovations Incorporated
LUNA
| $120K | ﹤0.01% |
20,645
+2
| +0% | +$12 |
|
2071
Destination XL Group
DXLG
$31.2M
| $117K | ﹤0.01% |
+34,557
| New | +$156K |
|
2072
8x8 Inc
EGHT
$324M
| $116K | ﹤0.01% |
22,465
-51,083
| -69% | -$428K |
|
2073
Evolus
EOLS
$500M
| $116K | ﹤0.01% |
10,002
-2,143
| -18% | -$25.3K |
|
|
CNSL
2074
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $116K | ﹤0.01% |
16,516
-155,751
| -90% | -$1.02M |
|
2075
Spero Therapeutics
SPRO
$71.2M
| $115K | ﹤0.01% |
+155,474
| New | +$452K |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.